Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
ACQUIRED COMPANY
 
My Lists

Telik  (Stock symbol: TELK ) Merged with MabVax Therapeutics (2014  amount undisclosed )

700 Hansen Way
Palo Alto, CA 94304
USA
(650)-845-7700
Website Company Summary Management Team
Board

Outside board: (May no longer be on the board) Edward Cantrall (Lederle Laboratories) Steven Goldring (Harvard Medical School Professor) Richard Newman (D&R Products Company) Herwig Von Morze (Heller Ehrman)
Former outside board: David Bethune (Atrix Labs CEO);  Annette Bianchi (Weiss, Peck & Greer);  Jean Deleage (Alta Partners);  Robert Frick (Bank of America) Jerrold Glick (National Health Labs);  Mary Ann Gray (Federated Kaufmann Fund) David Martin (Solexa);  Stefan Ryser (Bear Stearns Health Innoventures)
Company

Business description: Telik, Inc. (Nasdaq: TELK) is a biopharmaceutical company working to discover, develop and commercialize small molecule drugs to treat cancer and other serious diseases for which there is significant demand for new therapies. Our most advanced drug development candidate is TELCYTA™ (TLK286), a novel tumor activated compound which is currently in a Phase 3 registration trial in advanced ovarian cancer, and in Phase 2 trials in non-small cell lung, ovarian and breast cancer. A second product candidate, TLK199, is in a Phase 1-2a clinical trial for the treatment of myelodysplastic syndrome, a form of pre-leukemia, and also may be useful for increasing blood cell levels depleted by cancer chemotherapy. In addition to these and other products in our cancer pipeline, we are developing potential new treatments for Type 2 diabetes and inflammation. Our product candidates were discovered using our proprietary technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates.
Partners include: Sanwa Kagaku
Capital

Rounds: 6
Capital raised: 57.4M
Ownership: Merged with MabVax Therapeutics (2014  amount undisclosed )
Stock Symbol: TELK

Last Tweets


 

Last Mentions


Overview
Record updated: Mar 2011
Sector: Biotech
Year Founded: 1986
Headcount: 151-200 as of May 2011
Rounds: 6
Capital Raised: 57.4M
Ownership: Merged with MabVax Therapeutics (2014  amount undisclosed )
Stock Symbol: TELK